close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by TriSalus Life Sciences

< Previous 1 2 Next >
News headline image
TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Reports Q2 2024 Financial Results and Business Update
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Reports Q1 2024 Financial Results and Business Update
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD™ Method with the TriNav™ Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting
From TriSalus Life Sciences
Via Business Wire
Tickers MTAC
News headline image
TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD™ Method in Stage IV Uveal Melanoma Patients With Liver Metastases
From TriSalus Life Sciences
Via Business Wire
Tickers MTAC
News headline image
TriSalus Life Sciences Highlights Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) Clinical Trial Progress and Pre-clinical Research Developments
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Provides Updates on Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) 01 and 02 Clinical Studies
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Become Publicly Traded Through Merger With MedTech Acquisition Corporation
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Provides Update on Development of Immunotherapy Platform Approach for Liver and Pancreatic Tumors
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Enrolls First Patient in PERIO-02 Clinical Trial, Studying the Delivery of SD-101 via Pressure-Enabled Drug Delivery in Adults with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
From TriSalus Life Sciences
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today